Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(11):1747–1753. doi: 10.1038/sj.bjc.6690592

Mathematical and experimental analysis of localization of anti-tumour antibody–enzyme conjugates

T L Jackson 1, S R Lubkin 1, N O Siemers 2, D E Kerr 2, P D Senter 2, J D Murray 1
PMCID: PMC2363130  PMID: 10468291

Abstract

Considerable research has been aimed at improving the efficacy of chemotherapeutic agents for cancer therapy. A promising two-step approach that is designed to minimize systemic drug toxicity while maximizing activity in tumours employs monoclonal antibody (mAb)–enzyme conjugates for the activation of anticancer prodrugs. We present, analyse and numerically simulate a mathematical model based on the biology of the system to study the biodistribution, pharmacokinetics and localization properties of mAb–enzyme conjugates in tumour tissue. The model predictions were compared with experimental observations and an excellent correlation was found to exist. In addition, the critical parameters affecting conjugate half-life were determined to be the inter-capillary half-distance and the antibody–antigen binding affinity. An approximation is presented relating the per cent injected dose per gram to inter-capillary half-distance and time. Finally, the model was used to examine various dosing strategies in an attempt to determine which regimen would provide the best biodistribution results. We compared the results of administering a uniform dose of fusion protein via bolus injection, multiple injections and continuous infusion. The model predicts that dosing strategy has little effect on the amount of conjugate that localizes in the tumour. © 1999 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (112.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baxter L. T., Jain R. K. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer. 1996 Feb;73(4):447–456. doi: 10.1038/bjc.1996.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baxter L. T., Jain R. K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989 Jan;37(1):77–104. doi: 10.1016/0026-2862(89)90074-5. [DOI] [PubMed] [Google Scholar]
  3. Baxter L. T., Jain R. K. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res. 1991 Jan;41(1):5–23. doi: 10.1016/0026-2862(91)90003-t. [DOI] [PubMed] [Google Scholar]
  4. Baxter L. T., Jain R. K. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvasc Res. 1991 Mar;41(2):252–272. doi: 10.1016/0026-2862(91)90026-8. [DOI] [PubMed] [Google Scholar]
  5. Baxter L. T., Yuan F., Jain R. K. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res. 1992 Oct 15;52(20):5838–5844. [PubMed] [Google Scholar]
  6. Bosslet K., Czech J., Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 1994 Apr 15;54(8):2151–2159. [PubMed] [Google Scholar]
  7. Eccles S. A., Court W. J., Box G. A., Dean C. J., Melton R. G., Springer C. J. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 1994 Oct 1;54(19):5171–5177. [PubMed] [Google Scholar]
  8. Gerlowski L. E., Jain R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986 May;31(3):288–305. doi: 10.1016/0026-2862(86)90018-x. [DOI] [PubMed] [Google Scholar]
  9. Kerr D. E., Schreiber G. J., Vrudhula V. M., Svensson H. P., Hellström I., Hellström K. E., Senter P. D. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. 1995 Aug 15;55(16):3558–3563. [PubMed] [Google Scholar]
  10. Krogh A. The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol. 1919 May 20;52(6):409–415. doi: 10.1113/jphysiol.1919.sp001839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Melton R. G., Sherwood R. F. Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst. 1996 Feb 21;88(3-4):153–165. doi: 10.1093/jnci/88.3-4.153. [DOI] [PubMed] [Google Scholar]
  12. Meyer D. L., Jungheim L. N., Law K. L., Mikolajczyk S. D., Shepherd T. A., Mackensen D. G., Briggs S. L., Starling J. J. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 1993 Sep 1;53(17):3956–3963. [PubMed] [Google Scholar]
  13. Nugent L. J., Jain R. K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res. 1984 Jan;44(1):238–244. [PubMed] [Google Scholar]
  14. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pietersz G. A., Rowland A., Smyth M. J., McKenzie I. F. Chemoimmunoconjugates for the treatment of cancer. Adv Immunol. 1994;56:301–387. doi: 10.1016/s0065-2776(08)60455-1. [DOI] [PubMed] [Google Scholar]
  16. Senter P. D., Wallace P. M., Svensson H. P., Vrudhula V. M., Kerr D. E., Hellström I., Hellström K. E. Generation of cytotoxic agents by targeted enzymes. Bioconjug Chem. 1993 Jan-Feb;4(1):3–9. doi: 10.1021/bc00019a001. [DOI] [PubMed] [Google Scholar]
  17. Siemers N. O., Kerr D. E., Yarnold S., Stebbins M. R., Vrudhula V. M., Hellström I., Hellström K. E., Senter P. D. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Bioconjug Chem. 1997 Jul-Aug;8(4):510–519. doi: 10.1021/bc9700751. [DOI] [PubMed] [Google Scholar]
  18. Springer C. J., Bagshawe K. D., Sharma S. K., Searle F., Boden J. A., Antoniw P., Burke P. J., Rogers G. T., Sherwood R. F., Melton R. G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer. 1991;27(11):1361–1366. doi: 10.1016/0277-5379(91)90010-b. [DOI] [PubMed] [Google Scholar]
  19. Svensson H. P., Vrudhula V. M., Emswiler J. E., MacMaster J. F., Cosand W. L., Senter P. D., Wallace P. M. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Cancer Res. 1995 Jun 1;55(11):2357–2365. [PubMed] [Google Scholar]
  20. Wallace P. M., MacMaster J. F., Smith V. F., Kerr D. E., Senter P. D., Cosand W. L. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 1994 May 15;54(10):2719–2723. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES